IL-NIELSENIQ
NielsenIQ (NIQ), the world leader in measurement and data analytics, is excited to announce that ‘NIQ Ask Arthur’- a groundbreaking GenAI-driven tool—has been integrated into NIQ Discover. This transformative solution offers AI-guided global search and personalized recommendations, streamlining data analysis and facilitating informed decision-making. Launching “NIQ Ask Arthur” marks an important milestone for NIQ Labs. Positioned as an innovation powerhouse, NIQ Labs is ready to accelerate the future of innovation by solving client problems and uncovering new pathways to growth. Coupled with investments, NIQ Labs taps into an extensive array of data assets, employing intuitive business intelligence tools and predictive analytics driven by generative AI (GenAI) and authoritative data science pioneering the next era of inventive products.
With conversational AI features, ‘NIQ Ask Arthur’ empowers users to delve deeper into datasets, revolutionizing data-driven choices and showcasing NielsenIQ's commitment to cutting-edge analytics.
NIQ Discover, a state-of-the-art data visualization solution, accelerates access to insights for CPG manufacturers and retailers. It creates fresh, user-friendly pathways to insights, leveraging the power of on-demand data across multiple data sets. NIQ Discover is designed to help CPG manufacturers and retailers get meaningful insights faster, and measure and track what’s most important to their business within a single, centralized platform.
NIQ Ask Arthur in NIQ Discover enables enhanced insights discovery, so users can efficiently uncover valuable information, enriching the brand story and democratizing data access. Current and new users can uncover meaningful information, trends, and patterns that may otherwise go unnoticed, leading them to the most relevant areas of analysis. At NIQ we provide the Full View™, and we maintain the highest standard of data accuracy and quality. GenAI will help NIQ Discover users decipher diverse formats and tackle complex business questions.
“The vision of leveraging AI to assist in data analysis and storytelling is incredibly powerful. Democratizing access to data and analytics is crucial in helping users make informed decisions and drive innovation. ‘NIQ Ask Arthur’ unlocks the power of analytics on the Discover platform,” says Troy Treangen, Chief Product Officer, NIQ.
NIQ Ask Arthur in Discover enables users to save time by proactively suggesting insights and simplifying data navigation through a seamless, conversational AI-powered experience.
With NIQ’s investment in the cutting edge NIQ Discover platform, combined with our diverse data types and deep industry expertise, NIQ Ask Arthur delivers unparalleled value to clients.
NIQ is best positioned to understand data and the business questions that help brands unravel their story. The company’s agility and rapid deployment strategies have facilitated remarkable technological advancement. In the past year, the NIQ Discover platform witnessed extraordinary growth, surging from 2,500 users in January 2023 to an impressive 40,000 across 71 countries today, showcasing the vast scale of NIQ’s technological expansion. This ability to rapidly deploy technology, enhance user engagement, and establish a global presence underscores NIQ’s unparalleled agility and innovation in the tech industry. These advancements facilitate accelerated insights across diverse industries, channels, and products, driving speed-to-insight at an unprecedented scale to deliver the Full View™.
About NIQ
NIQ is the world’s leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. NIQ combined with GfK in 2023, bringing together the two industry leaders with unparalleled global reach. Today NIQ has operations in 95+ countries representing 97% of the world’s GDP. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full ViewTM.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513168921/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 18:22:00 CEST | Press release
Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 17:45:00 CEST | Press release
Celltrion’s Omlyclo™, the first and only omalizumab biosimilar in Europe, will be commercially available starting in Norway, with subsequent rollouts in European countries Results from the global Phase III clinical trial of Omlyclo™ (CT-P39) for the treatment of chronic spontaneous urticaria (CSU), allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) will be presented at a satellite symposium during the 2025 European Academy of Dermatology and Venereology (EADV) Congress Celltrion highlights the strength of its expanding dermatology portfolio with positive clinical results for CT-P55, a biosimilar candidate referencing secukinumab With the launch of Omlyclo™, Celltrion underscores its commitment to advancing innovative and accessible treatments in immunology and dermatology Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereo
Andersen Consulting tilføjer samarbejdsfirmaet Charter18.9.2025 17:14:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine digitale transformationskapaciteter gennem en samarbejdsaftale med Charter, et canadisk konsulentfirma, der er specialiseret i IT-strategi, managed services og applikationslevering. Charter blev grundlagt i 1997 og leverer teknologiprojekter med en forretningsorienteret tankegang og dyb teknisk ekspertise, herunder inden for IT-rådgivning, cloud-infrastruktur, cybersikkerhed, applikationsudvikling, projektlevering og forretningsarkitektur. Charter hjælper traditionelle virksomheder, offentlige institutioner, tjenesteudbydere og mellemstore kunder med implementering, netværksinfrastruktur og kundeorienterede applikationer – der leveres gennem en livscyklus-tilgang fra strategi til udførelse. "Vores mål hos Charter har altid været at fjerne kompleksiteten fra IT og hjælpe organisationer med at bevæge sig fremad med tillid," siger Kelly Michell, præsident for Charter. "Vores samarbejde med Andersen Consulting gør det muligt for os at bringe vores integrere
Andersen Consulting udvider sit udbud inden for cybersikkerhed og teknologi med tilføjelsen af Move18.9.2025 17:06:00 CEST | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Move, der er en førende virksomhed inden for it-infrastruktur, driftstjenester og digitale løsninger til virksomheder. Move befinder sig i Norge og Sverige. Move blev grundlagt i 1989 og leverer konsulentydelser, it-løsninger og driftstjenester. Virksomheden har ekspertise inden for cybersikkerhed, cloud-løsninger, server- og lagringsløsninger, netværkskommunikation og implementering af AI. Move samarbejder med mellemstore og store virksomheder om at designe, implementere og drive sikre, skalerbare og fremtidssikrede it-miljøer. "Dette samarbejde er en spændende mulighed for at skabe endnu større værdi for vores kunder," siger Roald Sannæs, der er administrerende direktør i Move. "Med vores kompetencer og Andersen Consultings globale rækkevidde og ekspertise kan vi levere mere helhedsorienterede løsninger, der hjælper organisationer med at løse nutidens udfordringer og forudse fremtidens muligheder." "Move har opbygget et godt ren
Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’18.9.2025 16:40:00 CEST | Press release
The inaugural ranking by TIME, in partnership with Statista, features AMRA as one of the world’s leading health technology companies that are “driving innovation, enhancing accessibility, and contributing to a more effective and sustainable health care system” AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918372780/en/ AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’ The selection, which comes just one week after celebrating AMRA’s 15 years of progress and innovation within the body composition space, highlights AMRA’s long-standing commitment to becoming a global leader in health informatics. By delivering detailed, reproduc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom